GlobeNewswire

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
22/04/2026
TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical [...]
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
22/04/2026
NRx has received a positive review letter (Discipline Review Letter) addressing Drug Quality requesting only “Minor” administrative changes NRx conducted a meeting with leadership of the FDA Office of Generic Drugs in [...]
Sironax Announces Abstract on SARM1 Inhibitor SIR2501 Selected for Presentation at 2026 ASCO Annual Meeting
22/04/2026
Poster presentation scheduled for May 30, 1:30-4:30 PM CDT WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for [...]
SEED Therapeutics Reports Tumor Eradication in a Neuroblastoma In Vivo Model with Clinical-Stage RBM39 Molecular Glue Degrader ST-01156
22/04/2026
Phase 1 Dose Escalation Underway at Six Leading U.S. Oncology Centers; MYC Overexpression and CDKN2A/B Deletion Identified as Potential Patient-Selection Biomarkers — Data Presented at AACR Annual Meeting 2026 KING OF [...]
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
22/04/2026
SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Grey Matters Announces Private Placement
22/04/2026
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “ Company ” or “ Grey Matters ”) ( [...]
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
22/04/2026
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions Strong industry reputation and commercial track record in [...]
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
22/04/2026
EMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE - a 38 [...]
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
22/04/2026
– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Growth and Raising 2026 [...]
Medicines360 and Pharma Dynamics announce the launch of Avibela® in South Africa, Expanding Access to Long‑Acting Contraception and Treatment of Heavy Menstrual Bleeding
22/04/2026
SAN FRANCISCO and CAPE TOWN, South Africa, April 22, 2026 (GLOBE NEWSWIRE) -- Medicines360 and Pharma Dynamics have announced the availability of AVIBELA, South Africa’s first generic levonorgestrel 52 mg intrauterine [...]
Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting
22/04/2026
AI-Designed Dual ATR-mTOR Inhibitor Demonstrates In Vivo Efficacy; Novel LNP Formulation of Bifunctional PARP/HDAC Inhibitor kt-3283 Successfully Characterized VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE [...]
Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman
22/04/2026
Appointment strengthens Elkedonia's governance as the company continues its development and prepares for its next phases of growth Pierre d’Epenoux is former CEO of ImCheck Therapeutics, a clinical-stage biotech immuno- [...]
Elkedonia renforce son Comité stratégique avec la nomination de Pierre d'Epenoux comme Président indépendant
22/04/2026
Cette nomination renforce la gouvernance d'Elkedonia alors que la société poursuit son développement et prépare ses prochaines étapes de croissance Pierre d'Epenoux est l'ancien Président Directeur Général d'ImCheck [...]
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
22/04/2026
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3 Tzield is the [...]
Communiqué de presse : Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants
22/04/2026
Tzield de Sanofi approuvé aux États-Unis pour retarder l’apparition du diabète de type 1 de stade 3 chez les jeunes enfants L'extension d'approbation inclut les enfants âgés d'un an et plus atteints de diabète de type 1 [...]
Axomove lève 4 M€ pour accélérer la commercialisation de son dispositif médical numérique de prévention et de rééducation
22/04/2026
Axomove lève 4 M€ pour accélérer la commercialisation de son dispositif médical numérique de prévention et de rééducation Ce tour d’investissement de série A est co-dirigé par le Fonds Prévention Numérique, géré par [...]
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
22/04/2026
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target action date for its [...]
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis
22/04/2026
Sanofi fait le point sur la soumission réglementaire de Sarclisa en formulation sous-cutanée aux États-Unis Paris, le 22 avril 2026 . La Food and Drug Administration (FDA) des États-Unis a prolongé de jusqu’à trois mois [...]
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
22/04/2026
New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda ® (tovorafenib) represents a rare [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum